Identification of Patients with Painful Diabetic Peripheral Neuropathy Who Have a Favorable Cost Profile with Pregabalin Treatment

Udall, Margarita; Mardekian, Jack; Cabrera, Javier

doi:10.1111/papr.12008

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though gabapentin has a favorable pharmacokinetic profile, it is only available in oral form and requires at least three times daily dosing in order to achieve mean plasma levels throughout a 24-hour period to achieve efficacy [13]. However, one benefit of the drug is that, unlike Prialt, it does not require laboratory monitoring [103, 104]. …”

Section: Examples Limitations and Pipeline Of Cav22-targeted Drugsmentioning

confidence: 99%

Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides

Feldman¹,

Khanna

2013

Neuroscience Letters

View full text Add to dashboard Cite

Chronic neuropathic pain management is a worldwide concern. Pharmaceutical companies globally have historically targeted ion channels as the therapeutic catechism with many blockbuster successes. Remarkably, no new pain therapeutic has been approved by European or American regulatory agencies over the last decade. This article will provide an overview of an alternative approach to ion channel drug discovery: targeting regulators of ion channels, specifically focusing on voltage-gated calcium channels. We will highlight the discovery of an anti-nociceptive peptide derived from a novel calcium channel interacting partner – the collapsin response mediator protein 2 (CRMP2). In vivo administration of this peptide reduces pain behavior in a number of models of neuropathic pain without affecting sympathetic-associated cardiovascular activity, memory retrieval, sensorimotor function, or depression. A CRMP2-derived peptide analgesic, with restricted access to the CNS, represents a completely novel approach to the treatment of severe pain with an improved safety profile. As peptides now represent one of the fastest growing classes of new drugs, it is expected that peptide targeting of protein interactions within the calcium channel complex may be a paradigm shift in ion channel drug discovery.

show abstract

Section: Examples Limitations and Pipeline Of Cav22-targeted Drugsmentioning

confidence: 99%

Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides

Feldman¹,

Khanna

2013

Neuroscience Letters

View full text Add to dashboard Cite

show abstract

Comorbidity Patterns and Its Impact on Health Outcomes: Two-Way Clustering Analysis

Ghosh

Cabrera

Adam

et al. 2020

IEEE Trans. Big Data

View full text Add to dashboard Cite

Identification of Patients with Painful Diabetic Peripheral Neuropathy Who Have a Favorable Cost Profile with Pregabalin Treatment

Abstract: The association of lower total costs among older individuals with pDPN who maintain high adherence to pregabalin therapy relative to key comparators suggests a pharmacoeconomic advantage of pregabalin in this population combined with a need for strategies promoting adherence.

Cited by 2 publications

References 38 publications

Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides

Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides

Comorbidity Patterns and Its Impact on Health Outcomes: Two-Way Clustering Analysis

Contact Info

Product

Resources

About